Vanessa A Hanger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Vanessa A Hanger has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Darae Ko
Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts, USA
1 shared publication - Emelia J. Benjamin
Boston University Chobanian & Avedisian School of Medicine
1 shared publication - Honghuang Lin
Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA
1 shared publication - Jelena Kornej
Boston University's and National Heart, Lung, and Blood Institute's Framingham Heart Study Framingham, MA United States
1 shared publication - Ludovic Trinquart
Tufts Clinical and Translational Sciences Institute, Tufts University, Boston, USA
1 shared publication Sarah R Preis
Department of Biostatistics, Boston University School of Public Health , Boston, MA
1 shared publication
Latest Publications
- Open Access
- 5 March 2021
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 117 (7) , 1632-1644
New biomarkers from multiomics approaches: improving risk prediction of atrial fibrillation
Atrial fibrillation (AF) is a common cardiac arrhythmia leading to many adverse outcomes and increased mortality. Yet the molecular mechanisms underlying AF remain largely unknown. Recent advances in high-throughput technologies make large-scale molecular profiling possible. In the past decade, multiomics studies of AF have identified a number of potential biomarkers of AF. In this review, we focus on the studies of multiomics profiles with AF risk. We summarize recent advances in the discovery of novel biomarkers for AF through multiomics studies. We also discuss limitations and future directions in risk assessment and discovery of therapeutic targets for AF.
- 5 March 2021
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 117 (7) , 1632-1644
Open AccessNew biomarkers from multiomics approaches: improving risk prediction of atrial fibrillation
Atrial fibrillation (AF) is a common cardiac arrhythmia leading to many adverse outcomes and increased mortality. Yet the molecular mechanisms underlying AF remain largely unknown. Recent advances in high-throughput technologies make large-scale molecular profiling possible. In the past decade, multiomics studies of AF have identified a number of potential biomarkers of AF. In this review, we focus on the studies of multiomics profiles with AF risk. We summarize recent advances in the discovery of novel biomarkers for AF through multiomics studies. We also discuss limitations and future directions in risk assessment and discovery of therapeutic targets for AF.